Literature DB >> 35906435

Perspectives Regarding Medications for Opioid Use Disorder Among Individuals with Mental Illness.

Derjung M Tarn1,2, Kevin J Shih3, Allison J Ober4, Sarah B Hunter4, Katherine E Watkins4, Jeremy Martinez5, Alanna Montero6, Michael McCreary6, Isabel Leamon4, John Sheehe5, Elizabeth Bromley6.   

Abstract

Most people with co-occurring opioid use disorder (OUD) and mental illness do not receive effective medications for treating OUD. To investigate perspectives of adults in a publicly-funded mental health system regarding medications for OUD (MOUD), we conducted semi-structured telephone interviews with 13 adults with OUD (current or previous diagnosis) receiving mental health treatment. Themes that emerged included: perceiving or using MOUDs as a substitute for opioids or a temporary solution to prevent withdrawal symptoms; negative perceptions about methadone/methadone clinics; and viewing MOUD use as "cheating". Readiness to quit was important for patients to consider MOUDs. All participants were receptive to discussing MOUDs with their mental health providers and welcomed the convenience of receiving care for their mental health and OUD at the same location. In conclusion, clients at publicly-funded mental health clinics support MOUD treatment, signaling a need to expand access and build awareness of MOUDs in these settings.
© 2022. The Author(s).

Entities:  

Keywords:  Buprenorphine-naloxone drug combination; Mental disorders; Narcotic antagonists; Opioid use disorders; Opioid-related disorders; Qualitative research

Year:  2022        PMID: 35906435     DOI: 10.1007/s10597-022-01012-x

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  29 in total

1.  Attitudes about medications for alcohol use disorder among individuals with serious mental illness: A health belief model analysis.

Authors:  Elizabeth Bromley; Derjung M Tarn; Michael McCreary; Brian Hurley; Allison J Ober; Katherine E Watkins
Journal:  J Subst Abuse Treat       Date:  2020-04-20

2.  Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors.

Authors:  I G Cabeza; M S Amador; C A López; M González de Chávez
Journal:  Schizophr Res       Date:  2000-01-21       Impact factor: 4.939

3.  Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study.

Authors:  Gilberto Gerra; Claudio Leonardi; Antonio D'Amore; Giovanni Strepparola; Roberto Fagetti; Cinzia Assi; Amir Zaimovic; Alfio Lucchini
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-11-23       Impact factor: 5.067

4.  Health beliefs and compliance with antipsychotic medication.

Authors:  R J Budd; I C Hughes; J A Smith
Journal:  Br J Clin Psychol       Date:  1996-09

5.  Use of mental health care and substance abuse treatment among adults with co-occurring disorders.

Authors:  Katherine M Harris; Mark J Edlund
Journal:  Psychiatr Serv       Date:  2005-08       Impact factor: 3.084

6.  Persistent Opioid Use Among Pediatric Patients After Surgery.

Authors:  Calista M Harbaugh; Jay S Lee; Hsou Mei Hu; Sean Esteban McCabe; Terri Voepel-Lewis; Michael J Englesbe; Chad M Brummett; Jennifer F Waljee
Journal:  Pediatrics       Date:  2017-12-04       Impact factor: 7.124

7.  Cost and utilization outcomes of opioid-dependence treatments.

Authors:  Onur Baser; Mady Chalk; David A Fiellin; David R Gastfriend
Journal:  Am J Manag Care       Date:  2011-06       Impact factor: 2.229

8.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

9.  Opioid use disorders, psychiatric comorbidities, and risk for suicide attempts among veterans seeking pain care.

Authors:  Lisham Ashrafioun; Kotwoallama R A Zerbo; Todd M Bishop; Peter C Britton
Journal:  Psychol Med       Date:  2019-09-16       Impact factor: 7.723

10.  Barriers and Facilitators to Clinician Readiness to Provide Emergency Department-Initiated Buprenorphine.

Authors:  Kathryn F Hawk; Gail D'Onofrio; Marek C Chawarski; Patrick G O'Connor; Ethan Cowan; Michael S Lyons; Lynne Richardson; Richard E Rothman; Lauren K Whiteside; Patricia H Owens; Shara H Martel; Edouard Coupet; Michael Pantalon; Leslie Curry; David A Fiellin; E Jennifer Edelman
Journal:  JAMA Netw Open       Date:  2020-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.